Program
Magnesium Chloride
Also written as “Custodiol” and “Nalmefene + 0.94% MgCl2”.
Its studies are mostly in Opiate Overdose · Diabetes Mellitus, Type 1 · Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. F. Köhler Chemie | 41 open or running | phase 3since Feb 14, 2014 | Sep 29, 2011 | Jan 2027phase 2 · NCT06032195 |
| Eli Lilly | 10 open or running | phase 1since Sep 28, 2021 | Sep 28, 2021 | none ahead |
| Knoa Pharma | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Relox Medical | 10 open or running | phase 3since Jun 30, 2009 | Jun 30, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2009First study: phase 3 study in StrokeNew to Relox MedicalRelox Medical · NCT00933868 · 81 enrolled · United States
- Sep 29, 2011Dr. F. Köhler Chemie's first study: phase 2 study in Coronary Artery DiseaseNew to Dr. F. Köhler ChemieDr. F. Köhler Chemie · NCT01444235 · 102 enrolled · Germany
- Feb 14, 2014Phase 3 study in Aortic Valve DiseaseDr. F. Köhler Chemie · NCT02098772 · 530 enrolled · Germany
- Aug 11, 2015Phase 3 study in Heart FailureDr. F. Köhler Chemie · NCT02869022 · 105 enrolled · Austria, Germany
- Sep 28, 2021Eli Lilly's first study: phase 1 study in Diabetes Mellitus, Type 1New to Eli LillyEli Lilly · NCT05067270 · 40 enrolled · Germany
- Aug 21, 2023Phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195 · 15 planned · Germany
- Apr 15, 2026Knoa Pharma's first study: phase 1 study in Opiate OverdoseNew to Knoa PharmaKnoa Pharma · NCT07543276 · 13 enrolled · United States
Ahead
- Jan 2027Primary completion: phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07543276Opiate Overdose · United States | 1 | Completed | Knoa Pharma | Apr 3, 2026 | 13 |
| NCT06032195Heart Transplantation · Germany | 2 | Recruiting | Dr. F. Köhler Chemie | Jan 2027 | 15 |
| NCT05067270Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Eli Lilly | Dec 6, 2021 | 40 |
| NCT02869022Heart Failure · Austria, Germany | 3 | Completed | Dr. F. Köhler Chemie | Sep 2, 2019 | 105 |
| NCT02098772Aortic Valve Disease · Germany | 3 | Completed | Dr. F. Köhler Chemie | Nov 16, 2018 | 530 |
| NCT01444235Coronary Artery Disease · Germany | 2 | Completed | Dr. F. Köhler Chemie | May 2012 | 102 |
| NCT00933868Stroke · United States | 3 | Completed | Relox Medical | May 2010 | 81 |
How it is read
Names in the registry
- “Custodiol”, 4 entries
- “Nalmefene + 0.94% MgCl2”, 2 entries
- “Magnesium Chloride”, 2 entries
Conditions, from the studies’ own filings
- Opiate Overdose, 1 study
- Diabetes Mellitus, Type 1, 1 study
- Aortic Valve Disease, 1 study
- Heart Failure, 1 study
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.